期刊论文详细信息
Health and Quality of Life Outcomes
Development and validation of the impact of dry eye on everyday life (IDEEL) questionnaire, a patient-reported outcomes (PRO) measure for the assessment of the burden of dry eye on patients
Robin Chalmers2  Rod Barnes5  Carolyn Begley3  Polyxane Mertzanis4  Krithika Rajagopalan1  Linda Abetz6 
[1] Sunovion Pharmaceuticals Inc. 84 Waterford Drive Marlborough, MA 01752, USA;Clinical Trial Consultant, 2097 East Lake Road, Atlanta, GA 30307, USA;Indiana University, School of Optometry, 800 East Atwater Avenue, Bloomington, IN 47405, USA;Independent consultant, Shrewsbury, MA, USA;Health Care Value Evidence, 6817 Lahontan Drive, Fort Worth, TX 76132, USA;Mapi Values, Adelphi Mill, Grimshaw Lane, Bollington, Cheshire, SK10 5JB, UK
关键词: questionnaire;    patient-reported outcome;    impact;    symptoms;    treatment satisfaction;    health-related quality of life;    non-Sjögren's keratoconjunctivitis sicca;    Sjögren's Syndrome;    Dry eye;   
Others  :  826182
DOI  :  10.1186/1477-7525-9-111
 received in 2011-08-17, accepted in 2011-12-08,  发布年份 2011
PDF
【 摘 要 】

Objective

To develop and validate a comprehensive patient-reported outcomes instrument focusing on the impact of dry eye on everyday life (IDEEL).

Methods

Development and validation of the IDEEL occurred in four phases: 1) focus groups with 45 dry eye patients to develop a draft instrument, 2) item generation, 3) pilot study to assess content validity in 16 patients and 4) psychometric validation in 210 subjects: 130 with non-Sjögren's keratoconjunctivitis sicca, 32 with Sjögren's syndrome and 48 controls, and subsequent item reduction.

Results

Focus groups identified symptoms and the associated bother, the impact of dry eye on daily life and the patients' satisfaction with their treatment as the central concepts in patients' experience of dry eye. Qualitative analysis indicated that saturation was achieved for these concepts and yielded an initial 112-item draft instrument. Patients understood the questionnaire and found the items to be relevant indicating content validity. Patient input, item descriptive statistics and factor analysis identified 55 items that could be deleted. The final 57-item IDEEL assesses dry eye impact constituting 3 modules: dry eye symptom-bother, dry eye impact on daily life comprising impact on daily activities, emotional impact, impact on work, and dry eye treatment satisfaction comprising satisfaction with treatment effectiveness and treatment-related bother/inconvenience. The psychometric analysis results indicated that the IDEEL met the criteria for item discriminant validity, internal consistency reliability, test-retest reliability and floor/ceiling effects. As expected, the correlations between IDEEL and the Dry Eye Questionnaire (a habitual symptom questionnaire) were higher than between IDEEL and Short-Form-36 and EuroQoL-5D, indicating concurrent validity.

Conclusion

The IDEEL is a reliable, valid and comprehensive questionnaire relevant to issues that are specific to dry eye patients, and meets current FDA patient-reported outcomes guidelines. The use of this questionnaire will provide assessment of the impact of dry eye on patient dry eye-related quality of life, impact of treatment on patient outcomes in clinical trials, and may aid in treatment effectiveness evaluation.

【 授权许可】

   
2011 Abetz et al; licensee BioMed Central Ltd.

【 预 览 】
附件列表
Files Size Format View
20140713085701482.pdf 1184KB PDF download
Figure 5. 59KB Image download
Figure 4. 54KB Image download
Figure 3. 50KB Image download
Figure 2. 102KB Image download
Figure 1. 84KB Image download
【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】
  • [1]Dry Eye Workshop: The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007, 5:75-92.
  • [2]Goto E, Yagi Y, Matsumoto Y, Tsubota K: Impaired functional visual acuity of dry eye patients. Am J Ophthalmol 2002, 133:181-186.
  • [3]Friedman NJ: Impact of dry eye disease and treatment on quality of life. Curr Opin Ophthalmol 2010, 21:310-316.
  • [4]Mertzanis P, Abetz L, Rajagopalan K, Espindle D, Chalmers R, Snyder C, Caffery B, Edrington T, Simpson T, Nelson JD, et al.: The relative burden of dry eye in patients' lives: comparisons to a U.S. normative sample. Invest Ophthalmol Vis Sci 2005, 46:46-50.
  • [5]Nichols KK, Mitchell GL, Zadnik K: Performance and repeatability of the NEI-VFQ-25 in patients with dry eye. Cornea 2002, 21:578-583.
  • [6]Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL: Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol 2000, 118:615-621.
  • [7]Miljanovic B, Dana R, Sullivan DA, Schaumberg DA: Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol 2007, 143:409-415.
  • [8]Nichols KK, Foulks GN, Bron AJ, Glasgow BJ, Dogru M, Tsubota K, Lemp MA, Sullivan DA: The International Workshop on Meibomian Gland Dysfunction: Executive summary. International Worshop on Meibomian Gland Dysfunction1922-1929.
  • [9]Pepose JS, Akata RF, Pflugfelder SC, Voigt W: Mononuclear cell phenotypes and immunoglobulin gene rearrangements in lacrimal gland biopsies from patients with Sjogren's syndrome. Ophthalmology 1990, 97:1599-1605.
  • [10]Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, Bjerrum KB, Braga S, Coll J, de Vita S, et al.: Preliminary criteria for the classification of Sjogren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993, 36:340-347.
  • [11]Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, et al.: Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002, 61:554-558.
  • [12]Perry HD: Dry eye disease: pathophysiology, classification, and diagnosis. Am J Manag Care 2008, 14:S79-S87.
  • [13]Begley CG, Chalmers RL, Abetz L, Venkataraman K, Mertzanis P, Caffery BA, Snyder C, Edrington T, Nelson D, Simpson T: The relationship between habitual patient-reported symptoms and clinical signs among patients with dry eye of varying severity. Invest Ophthalmol Vis Sci 2003, 44:4753-4761.
  • [14]McCarty CA, Bansal AK, Livingston PM, Stanislavsky YL, Taylor HR: The epidemiology of dry eye in Melbourne, Australia. Ophthalmology 1998, 105:1114-1119.
  • [15]McMonnies CW: Key questions in a dry eye history. J Am Optom Assoc 1986, 57:512-517.
  • [16]Schein OD, Munoz B, Tielsch JM, Bandeen-Roche K, West S: Prevalence of dry eye among the elderly. Am J Ophthalmol 1997, 124:723-728.
  • [17]Chalmers RL, Begley CG, Edrington T, Caffery B, Nelson D, Snyder C, Simpson T: The agreement between self-assessment and clinician assessment of dry eye severity. Cornea 2005, 24:804-810.
  • [18]Sullivan BD, Whitmer D, Nichols KK, Tomlinson A, Foulks GN, Geerling G, Pepose JS, Kosheleff V, Porreco A, Lemp MA: An objective approach to dry eye disease severity. Invest Ophthalmol Vis Sci 2010, 51:6125-6130.
  • [19]Abetz L, Chalmers R, Begley C, Mertzanis P, Venkataraman K, Barnes R, IDEEL Study Group: The Impact of Dry Eye on Everyday Life (IDEEL) questionnaire: saturation, reliability, validity and discriminative ability compared to generic measures. 2010.
  • [20]Rajagopalan K, Abetz L, Mertzanis P, Espindle D, Begley C, Chalmers R, Caffery B, Snyder C, Nelson JD, Simpson T, et al.: Comparing the discriminative validity of two generic and one disease-specific health-related quality of life measures in a sample of patients with dry eye. Value Health 2005, 8:168-174.
  • [21]Nichols KK, Nichols JJ, Mitchell GL: The lack of association between signs and symptoms in patients with dry eye disease. Cornea 2004, 23:762-770.
  • [22]Moss SE, Klein R, Klein BE: Long-term incidence of dry eye in an older population. Optom Vis Sci 2008, 85:668-674.
  • [23]Dry Eye Workshop: Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007, 5:163-178.
  • [24]Sall K, Stevenson OD, Mundorf TK, Reis BL: Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000, 107:631-639.
  • [25]Manthorpe R, Asmussen K, Oxholm P: Primary Sjogren's syndrome: diagnostic criteria, clinical features, and disease activity. J Rheumatol Suppl 1997, 50:8-11.
  • [26]Bandeen-Roche K, Munoz B, Tielsch JM, West SK, Schein OD: Self-reported assessment of dry eye in a population-based setting. Invest Ophthalmol Vis Sci 1997, 38:2469-2475.
  • [27]Begley CG, Caffery B, Nichols K, Mitchell GL, Chalmers R: Results of a dry eye questionnaire from optometric practices in North America. Adv Exp Med Biol 2002, 506:1009-1016.
  • [28]Bowman SJ, Booth DA, Platts RG, Field A, Rostron J: Validation of the Sicca Symptoms Inventory for clinical studies of Sjogren's syndrome. J Rheumatol 2003, 30:1259-1266.
  • [29]Doughty MJ, Fonn D, Richter D, Simpson T, Caffery B, Gordon K: A patient questionnaire approach to estimating the prevalence of dry eye symptoms in patients presenting to optometric practices across Canada. Optom Vis Sci 1997, 74:624-631.
  • [30]Oden NL, Lilienfeld DE, Lemp MA, Nelson JD, Ederer F: Sensitivity and specificity of a screening questionnaire for dry eye. Adv Exp Med Biol 1998, 438:807-820.
  • [31]Abetz L, Venkataraman K, Mertzanis P, Chalmers R, Begley C: The Development, Reliability and Validity of a Questionnaire to Assess the Impact of Dry Eyes on Everyday Life (IDEEL). Associaiton for Research in Vision and Ophthalmology 2003, 44.
  • [32]Fairchild CJ, Chalmers RL, Begley CG: Clinically important difference in dry eye: change in IDEEL-symptom bother. Optom Vis Sci 2008, 85:699-707.
  • [33]Daniels TE: Labial salivary gland biopsy in Sjogren's syndrome. Assessment as a diagnostic criterion in 362 suspected cases. Arthritis Rheum 1984, 27:147-156.
  • [34]Charmaz K: Grounded Theory in the 21st century. In The Sage Handbook of Qualitative research. 3rd edition. Edited by Denzin NK, Lincoln YS. Thousand Oaks, CA: Sage; 2005.
  • [35]Murh T: User's Manual for Atlas.ti 6.0. Berlin: Berlin, Atlas.ti; 2004.
  • [36]Guest G, Bunce A, Johnson L: How many interviews are enough? An experiment with data saturation variability. Field Methods 2006, 18:59-82.
  • [37]Sandelowski M: Sample size in qualitative research. Research in Nursing and Health 1995, 18:179-183.
  • [38]Strauss A, Corbin J: Basics of qualitative research: Techniques and procedures for developing Grounded Theory. London: Sage; 1998.
  • [39]Ware JE: SF-36 Health Survey - Manual and Interpretation Guide. Boston: The Health Institute, New England Medical Center; 1993.
  • [40]Begley CG, Caffery B, Chalmers RL, Mitchell GL: Use of the dry eye questionnaire to measure symptoms of ocular irritation in patients with aqueous tear deficient dry eye. Cornea 2002, 21:664-670.
  • [41]The EuroQoL Group: EuroQoL - a facility for the measurement of health-related quality of life. Health Policy 1990, 16:199-208.
  • [42]Nunnally JC, Bernstein IH: Psychometric theory. New York: McGraw-Hill Inc; 1994.
  • [43]Hays RD, Hayashi T: Beyond internal consistency reliability: rationale and user's guide for Multitrait analysis program on the microcomputer. Behav Res Methods Instrum Comput 1990, 22:167-175.
  • [44]Cronbach LJ: Coefficient Alpha and the Internal Structure of Tests. Psychometrika 1951, 16:297-334.
  • [45]Deyo RA, Diehr P, Patrick DL: Reproducibility and Responsiveness of Health Status Measures. Statistics and Strategies for Evaluation. Control Clin Trials 1991, 142-158.
  • [46]Chassany O, Sagnier P, Marquis P, Fullerton S, Aaronson N: Patient-reported outcomes: The example of health-related quality of life: A European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Inf J 2002, 36:209-238.
  • [47]Schipper H: Guidelines and caveats for quality of life measurement in clinical practice and research. Oncology (Williston Park) 1990, 4:51-57.
  • [48]Shikiar R, Rentz AM: Satisfaction with medication: an overview of conceptual, methodologic, and regulatory issues. Value Health 2004, 7:204-215.
  • [49]Wilson IB, Cleary PD: Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA 1995, 273:59-65.
  • [50]Mizuno Y, Yamada M, Miyake Y: Association between clinical diagnostic tests and health-related quality of life surveys in patients with dry eye syndrome. Jpn J Ophthalmol 2010, 54:259-265.
  • [51]Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims [http:/ / www.fda.gov/ downloads/ Drugs/ GuidanceComplianceRegulatoryInforma tion/ Guidances/ UCM193282.pdf] webcite
  • [52]Oliver RL: Satisfaction: A Behavioral Perspective on the Consumer. New York: McGraw-Hill; 1997.
  • [53]Dry Eye Workshop: Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007, 5:108-152.
  • [54]Lemp MA, Bron AJ, Baudouin C, itez Del Castillo JM, Geffen D, Tauber J, Foulks GN, Pepose JS, Sullivan BD: Tear osmolarity in the diagnosis and management of dry eye disease. Am J Ophthalmol 2011, 151:792-798.
  • [55]Buchholz P, Steeds CS, Stern LS, Wiederkehr DP, Doyle JJ, Katz LM, Figueiredo FC: Utility assessment to measure the impact of dry eye disease. Ocul Surf 2006, 4:155-161.
  • [56]Baudouin C, Creuzot-Garcher C, Hoang-Xuan T, Rigeade MC, Brouquet Y, Bassols A, Benmedjahed K, Arnould B: [Creating a specific diagnostic and quality-of-life questionnaire for patients with ocular surface disease]. J Fr Ophtalmol 2003, 26:119-130.
  • [57]Baudouin C, Creuzot-Garcher C, Hoang-Xuan T, Rigeade MC, Brouquet Y, Bassols A, Guillemin I, Benmedjahed K, Arnould B: Severe impairment of health-related quality of life in patients suffering from ocular surface diseases. J Fr Ophtalmol 2008, 31:369-378.
  • [58]Foulks GN, Sindt C, Griffin J: Efficacy evaluation of a novel emulsion-based, anionic phospholipid-containing artificial tear in meibomian gland dysfunction subjects. 6th International Conference of the Tear Film and Ocular Society (TFOS) 2010.
  文献评价指标  
  下载次数:132次 浏览次数:11次